This article is a correction to the text on the current consensus on ulcerative colitis and the evidence for the influence of the intestinal microflora on this disease. Ulcerative colitis is a chronic inflammatory disease of the colon and rectum that affects the inner mucosa and can lead to ulcers and bleeding. The main symptoms include diarrhea with blood or mucus, abdominal pain, cramping, rectal bleeding, stool urgency, weight loss, fatigue, and anemia. In Slovakia, it affects approximately 15,000 patients, mainly young people aged 15-25, and its number is expected to increase by 30% in the next ten years. Treatment includes corticosteroids, 5-aminosalicylates with an efficacy of around 55–80% for inducing remission, immunomodulators such as azathioprine, and biologics such as infliximab or adalimumab. The acute severe form (ASUC) has a mortality of 1.1–2.9% and requires surgery in 30% of patients. The disease increases the risk of colorectal cancer twice compared to the general population and can also affect the eyes, joints or skin.[1][2][3][4][5][6]